Harold Bernstein, President of Research and Development (R&D) and Chief Medical Officer (CMO) at Maze Therapeutics, Inc. (MAZE), sold 16,142 shares of the company at a per-share price of $27.61, totaling $445,620, according to data filed with the SEC.
Who is Harold Bernstein and What is His Real Role at Maze Therapeutics?
Harold Bernstein holds the position of President of R&D and CMO at Maze Therapeutics, meaning he leads the company's research and development strategy as well as its medical affairs. In this role, he has access to privileged information regarding product development projects, clinical trials, and new drug launch strategies. This places him in a unique position to assess the company's future prospects.
As part of the executive team, Harold Bernstein is involved in making strategic decisions that impact the direction and growth of the company. His role also entails managing relationships with stakeholders, including investors, commercial partners, and regulatory authorities. This position provides him with a deep understanding of the company, its strengths and weaknesses, as well as market challenges and opportunities.
Access to privileged information is a key aspect of Harold Bernstein's role. As a leader, he is aware of the latest developments in research, clinical trial results, and plans for new product launches. This enables him to make informed decisions regarding his personal investments in the company, including the sale of shares.
Transaction Details: 16,142 shares at $27.61 each
The transaction carried out by Harold Bernstein involves the sale of 16,142 Maze Therapeutics shares at a price of $27.61 per share. It is important to note that the per-share price and the total transaction value are two distinct figures. In this case, the per-share price is $27.61, while the total transaction value, representing the amount received by Harold Bernstein, is $445,620.
The date of the transaction, according to available data, is August 16, 2026. This information is filed with the SEC under Form 4 regulations, which require company executives and board members to disclose their stock transactions in the company within two business days of the transaction.
Why Insiders Sell Their Shares â Possible Reasons
There are several reasons why insiders like Harold Bernstein might choose to sell their shares. Portfolio diversification is one such reason. Executives may opt to sell some of their shares to spread their investments and manage risk. Tax planning is another reason, as selling shares can be done to meet tax obligations or take advantage of favorable tax conditions.
Personal liquidity is also a reason why insiders might sell their shares. Executives may need cash for personal expenses, such as purchasing a home, funding children's education, or covering unforeseen expenses. In such cases, selling shares can be a way to generate funds without incurring debt.
It is also possible that the sale of shares could be interpreted as a bearish signal, suggesting that the insider has concerns about the company's future prospects. However, it is important to qualify this
